Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Dose-Escalation Study of the Hedgehog Smoothened Antagonist GDC-0449 (NSC 747691) Plus Pan-Notch Inhibitor RO4929097 (NSC 749225) Administered in Patients With Advanced Breast Cancer.

Next Previous
Search
Trial Profile

A Phase I Dose-Escalation Study of the Hedgehog Smoothened Antagonist GDC-0449 (NSC 747691) Plus Pan-Notch Inhibitor RO4929097 (NSC 749225) Administered in Patients With Advanced Breast Cancer.

Status: Discontinued
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RG 4733 (Primary) ; Vismodegib (Primary)
  • Indications Advanced breast cancer
  • Focus Adverse reactions

Most Recent Events

  • 14 Apr 2015 Status changed from active, no longer recruiting to discontinued as per ClinicalTrials.gov record.
  • 24 Jan 2014 Status changed from recruiting to active, no longer recruiting; according to CLinicalTrials.gov record.
  • 23 Aug 2013 Planned End Date changed from 1 Sep 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top